Relay Therapeutics, Inc. Common Stock
Here’s whether Relay Therapeutics, Inc. Common Stock (RLAY) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+4.34% over 10 days); RSI 55 — healthy momentum range; strong 1-year return of +375.6%; 3-month momentum positive (+47.4%); rising volume confirms the move (1.43x 30d avg). Currently 21.9% off its 52-week high. Score: +8/7.
RLAY is in a confirmed uptrend, trading above both its 50-day ($12.79) and 200-day ($8.32) moving averages. An RSI of 55.3 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +375.6% compares to +27.9% for SPY (beat the market by 347.7%). The current 21.9% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.